The study did not include rare sequence types or isolates from the Kinki region (Osaka), where *bla*IMP-6 is prevalent, meaning the findings may not fully represent the entire country's epidemiology.
Absence of Patient-Level Clinical Data
Without patient-specific clinical information like movement between wards or clinical outcomes, the researchers could not differentiate between infection and colonization or reconstruct precise transmission pathways, limiting the depth of epidemiological analysis.
PCR screening focused only on major carbapenemase genes, potentially missing uncommon variants or non-enzymatic resistance mechanisms (e.g., porin loss, AmpC overexpression), which could lead to an incomplete picture of resistance mechanisms.
Draft Genome Assembly Gaps
Using draft genome assemblies may have obscured certain genetic elements like specific antimicrobial resistance genes, mobile genetic elements, or plasmid replication genes, which are crucial for understanding resistance dynamics.
An overrepresentation of isolates from one high-burden facility and variable participation rates among hospitals could have introduced sampling bias, potentially affecting the observed distribution of sequence types and generalizability to the nationwide CPEC epidemiology.
Discordance Between Phenotypic and Genotypic Resistance
Some isolates carrying *bla*IMP-1 genes showed low meropenem MICs (phenotypic susceptibility), highlighting the challenge of relying solely on phenotypic screening and the need for molecular confirmation.